10:29 AM EDT, 07/03/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Wednesday that Health Canada has approved Rybrevant in combination with platinum-based chemotherapy to treat adults with locally advanced or metastatic non-small cell lung cancer with activating epidermal growth factor receptor Exon 20 insertion mutations.

The approval was based on results from a phase 3 study that showed that the combination therapy provides a "clinically meaningful and statistically significant improvement" in progression-free survival and a 60% reduction in the risk of disease progression or death compared with chemotherapy alone.

Shares of the company were down 0.7% in recent Wednesday trading.

Price: 144.98, Change: -1.06, Percent Change: -0.72